Lepu Biopharma Co., Ltd.
Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on developing oncology therapeutics with a pipeline designed with a range of oncology products in China. The company develops oncology drug candidates, including antibody-drug conjugates (ADC…
Biotechnology
CN, Shanghai [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -100.00 | -30.32 | 0.00 | |
| Graham Fair Price | 100.00 | 0.97 | 0.00 | |
| PEG | 0.00 | 0.00 | 0.00 | |
| Price/Book | 100.00 | 7.06 | 0.00 | |
| Price/Cash Flow | -100.00 | -28.89 | 0.00 | |
| Prices/Earnings | 100.00 | 12.23 | 0.00 | |
| Price/Sales | 100.00 | 81.61 | 0.00 | |
| Price/FCF | -100.00 | -28.89 | 0.00 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -100.00 | -0.02 | 0.00 | |
| Operating Margin | -100.00 | -3.54 | 0.00 | |
| ROA | n.A. | 0.05 | n.A. | |
| ROE | n.A. | 0.14 | n.A. | |
| ROIC | n.A. | -0.54 | n.A. | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.04 | -0.07 | -46.36 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 0.00 | 0.00 | 0.00 | |
| EPS QOQ | 0.00 | 0.00 | 0.00 | |
| FCF QOQ | 0.00 | 0.00 | 0.00 | |
| Revenue QOQ | 0.00 | 0.00 | 0.00 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Weak
Fundamentals
Leverage & Liquidity
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 33.31 | 100.00 | |
| Days Sales Outstanding (DSO) | 0.00 | 43.86 | 100.00 | |
| Inventory Turnover | n.A. | 2.70 | n.A. | |
| Debt/Capitalization | 0.44 | 0.45 | 2.15 | |
| Quick Ratio | 0.53 | 0.59 | 11.60 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q2 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | 0.00 | 0.54 | 100.00 | |
| Cash | 0.00 | 0.30 | 100.00 | |
| Capex | 0.00 | -0.01 | -100.00 | |
| Free Cash Flow | 0.00 | -0.13 | -100.00 | |
| Revenue | 0.00 | 0.05 | 100.00 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Positive
Fundamentals
Financial Health
06 - Financial Health ·
Bad